These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 16981822)

  • 1. The therapeutic potential of CD39: interview with Dr Simon Robson by Emma Quigley.
    Robson S
    Expert Opin Ther Targets; 2006 Oct; 10(5):649-52. PubMed ID: 16981822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ecto-nucleotidases of the CD39/NTPDase family modulate platelet activation and thrombus formation: Potential as therapeutic targets.
    Atkinson B; Dwyer K; Enjyoji K; Robson SC
    Blood Cells Mol Dis; 2006; 36(2):217-22. PubMed ID: 16476557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycogen synthase kinase-3--a promising therapeutic target: Dr Hagit Eldar-Finkelman interviewed by Emma Quigley.
    Eldar-Finkelman H
    Expert Opin Ther Targets; 2006 Apr; 10(2):199-201. PubMed ID: 16548769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell adhesion molecules as therapeutic targets: interview with Professor Michael P Schön. Interviewed by Emma Quigley.
    Schön MP
    Expert Opin Ther Targets; 2006 Dec; 10(6):799-802. PubMed ID: 17105368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibiting angiogenesis: interview with Dr Jean Plouët. Interview by Emma Quigley.
    Plouët J
    Expert Opin Ther Targets; 2006 Aug; 10(4):501-3. PubMed ID: 16848687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new therapeutic target for atherosclerosis treatment: interview with Uday Saxena. Interviewed by Emma Quigley.
    Saxena U
    Expert Opin Ther Targets; 2006 Feb; 10(1):1-3. PubMed ID: 16441223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current targets in irritable bowel syndrome: an interview with Eamonn Quigley. Interview by Emma Quigley.
    Quigley E
    Expert Opin Ther Targets; 2006 Jun; 10(3):351-3. PubMed ID: 16706675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting stenosis with nucleotide-hydrolyzing enzymes.
    Kaczmarek E; Koziak K
    Curr Pharm Biotechnol; 2011 Nov; 12(11):1799-804. PubMed ID: 21902627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic control of excessive extracellular nucleotide accumulation by CD39/ecto-nucleotidase-1: implications for ischemic vascular diseases.
    Marcus AJ; Broekman MJ; Drosopoulos JH; Islam N; Pinsky DJ; Sesti C; Levi R
    J Pharmacol Exp Ther; 2003 Apr; 305(1):9-16. PubMed ID: 12649347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond ecto-nucleotidase: CD39 defines human Th17 cells with CD161.
    Bai A; Robson S
    Purinergic Signal; 2015 Sep; 11(3):317-9. PubMed ID: 26059452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation.
    Robson SC; Wu Y; Sun X; Knosalla C; Dwyer K; Enjyoji K
    Semin Thromb Hemost; 2005 Apr; 31(2):217-33. PubMed ID: 15852225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ecto-ATP diphosphohydrolase/CD39 is overexpressed in differentiated human melanomas.
    Dzhandzhugazyan KN; Kirkin AF; thor Straten P; Zeuthen J
    FEBS Lett; 1998 Jul; 430(3):227-30. PubMed ID: 9688544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ecto-nucleotidases of ectonucleoside triphosphate diphosphohydrolase family: structure, localization and functional significance].
    Iablons'ka SV; Rybal'chenko VK
    Ukr Biokhim Zh (1999); 2010; 82(3):5-17. PubMed ID: 21328873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RanBPM associates with CD39 and modulates ecto-nucleotidase activity.
    Wu Y; Sun X; Kaczmarek E; Dwyer KM; Bianchi E; Usheva A; Robson SC
    Biochem J; 2006 May; 396(1):23-30. PubMed ID: 16478441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice.
    Jackson SW; Hoshi T; Wu Y; Sun X; Enjyoji K; Cszimadia E; Sundberg C; Robson SC
    Am J Pathol; 2007 Oct; 171(4):1395-404. PubMed ID: 17823293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs.
    Reutershan J; Vollmer I; Stark S; Wagner R; Ngamsri KC; Eltzschig HK
    FASEB J; 2009 Feb; 23(2):473-82. PubMed ID: 18838482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of the T Cell Response by CD39.
    Takenaka MC; Robson S; Quintana FJ
    Trends Immunol; 2016 Jul; 37(7):427-439. PubMed ID: 27236363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of ATP diphosphohydrolase/CD39 in human vascular endothelial cells.
    Imai M; Kaczmarek E; Koziak K; Sévigny J; Goepfert C; Guckelberger O; Csizmadia E; Schulte Am Esch J; Robson SC
    Biochemistry; 1999 Oct; 38(41):13473-9. PubMed ID: 10521254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Making melanoma therapy personal: an interview with Dr Keiran Smalley for
    Smalley KS
    Melanoma Manag; 2017 May; 4(2):95-97. PubMed ID: 30190911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of purinergic vascular regulation in the colon during colitis is associated with upregulation of CD39.
    Neshat S; deVries M; Barajas-Espinosa AR; Skeith L; Chisholm SP; Lomax AE
    Am J Physiol Gastrointest Liver Physiol; 2009 Feb; 296(2):G399-405. PubMed ID: 19074640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.